These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The emerging risk factors for cardiovascular disease: a review of the epidemiologic evidence for lipoprotein(a), homocysteine, and fibrinogen. Catena C; Cavarape A; Dotto L; Colussi G; Novehllo M; De Marchi S; Sechi LA Adv Clin Path; 2003 Jan; 7(1):3-11. PubMed ID: 19774732 [TBL] [Abstract][Full Text] [Related]
11. Non-traditional risk factors for atherosclerosis. Acevedo M; Tagle R; Simpfendorfer C Rev Med Chil; 2001 Oct; 129(10):1212-21. PubMed ID: 11775351 [TBL] [Abstract][Full Text] [Related]
12. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Massy ZA Nephrol Dial Transplant; 2000; 15 Suppl 5():81-91. PubMed ID: 11073279 [No Abstract] [Full Text] [Related]
13. Homocysteine and other cardiovascular risk factors in patients with lichen planus. Saleh N; Samir N; Megahed H; Farid E J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1507-13. PubMed ID: 24330130 [TBL] [Abstract][Full Text] [Related]
14. Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Naruszewicz M; Klinke M; Dziewanowski K; Staniewicz A; Bukowska H Metabolism; 2001 Feb; 50(2):131-4. PubMed ID: 11229418 [TBL] [Abstract][Full Text] [Related]
15. Homocysteine and occlusive arterial disease. O'Grady H; Kelly C; Bouchier-Hayes D; Leahy A Br J Surg; 2002 Jul; 89(7):838-44. PubMed ID: 12081732 [TBL] [Abstract][Full Text] [Related]
16. History of emerging vascular disease risk factors. Pilgeram L JAMA; 2004 Nov; 292(17):2086; author reply 2086. PubMed ID: 15523068 [No Abstract] [Full Text] [Related]
17. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease. Kronenberg F Curr Opin Nephrol Hypertens; 1998 May; 7(3):271-8. PubMed ID: 9617557 [TBL] [Abstract][Full Text] [Related]
18. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Eikelboom JW; Hankey GJ Curr Opin Nephrol Hypertens; 2001 May; 10(3):377-83. PubMed ID: 11342801 [TBL] [Abstract][Full Text] [Related]
19. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. Zakai NA; Katz R; Jenny NS; Psaty BM; Reiner AP; Schwartz SM; Cushman M J Thromb Haemost; 2007 Jun; 5(6):1128-35. PubMed ID: 17388967 [TBL] [Abstract][Full Text] [Related]
20. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Alfthan G; Pekkanen J; Jauhiainen M; Pitkäniemi J; Karvonen M; Tuomilehto J; Salonen JT; Ehnholm C Atherosclerosis; 1994 Mar; 106(1):9-19. PubMed ID: 8018111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]